Compare iShares Core High Dividend ETF (HDV) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs Medpace Holdings Inc — how do they compare? iShares Core High Dividend ETF trades at $28.24, while Medpace Holdings Inc trades at $530 (market cap $15.08B). The key difference: iShares Core High Dividend ETF is trading nearer its 52-week high, Medpace Holdings Inc nearer its low. Which is the better fit depends on your goals.
| HDV | MEDP | |
|---|---|---|
52-Week High | $28.36 | $620.59 |
52-Week Low | $23.64 | $308.88 |
Market Cap | — | $15.08B |
Sector | — | Technology |
Enterprise Value | — | $14.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV trades at $28.18, down 0.25% on the day, with technical indicators showing a bullish trend supported by moving averages. Recent corporate actions include a 1:5 stock split in April 2026 and scheduled dividends for mid-2026. The ETF focuses on high-quality, high-yield U.S. large-cap value stocks, emphasizing defensive sectors like healthcare and energy.
Outlook remains positive due to strong technical momentum and quality screening, but risks include sector concentration in energy, which may introduce volatility. The ETF's low beta and focus on dividend sustainability appeal to income-focused investors, though competition from lower-cost alternatives like SCHD warrants monitoring.
MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.
The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
